O'Keeffe Charles B 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Dec 11, 2024
Insider Transaction Report
Form 4
O'Keeffe Charles B
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2024-12-10$4.01/sh+40,000$160,400→ 727,137 total - Exercise/Conversion
Common Stock, par value $0.001 per share
2024-12-09+1,413→ 687,137 total - Exercise/Conversion
Restricted Stock Units
2024-12-09−1,413→ 253,607 total→ Common Stock (1,413 underlying) - Exercise/Conversion
Options to purchase common stock
2024-12-10−40,000→ 213,607 totalExercise: $4.01Exp: 2025-01-02→ Common Stock (40,000 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- [F2]Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026.
- [F3]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 9, 2024.
- [F4]Options vested in three annual tranches beginning on January 2, 2019.